Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Entinostat + Medroxyprogesterone|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Entinostat||HDAC inhibitor SNDX-275|MS 275||HDAC Inhibitor 41||Entinostat (MS-275) inhibits HDAC activity, with selectivity towards HDAC1, 2, and 3, which results in increased histone acetylation, and potentially leads to decreased tumor cell proliferation and tumor growth (PMID: 19724929, PMID: 17383217, PMID: 32503469).|
|Medroxyprogesterone||Depo-Provera||CBP-1011||Hormone - Anti-estrogens 24||Depo-Provera (medroxyprogesterone) is a synthetic progesterone derivative that acts as an anti-estrogen by binding to and activating nuclear receptors, stimulating downstream signaling and potentially resulting in decreased growth of estrogen-sensitive tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03018249||Phase II||Medroxyprogesterone Entinostat + Medroxyprogesterone||Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer||Completed||USA||0|